These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8554031)

  • 1. A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer.
    Erlichman C; Fine S; Kerr I; Hoffmann W; Gorg C; Schmoll HJ; Preusser P; Thuerlimann B; Gustavsson B
    Am J Clin Oncol; 1996 Feb; 19(1):26-31. PubMed ID: 8554031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
    J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association.
    Atkins JN; Muss HB; Case LD; Richards F; Grote T; McFarland J
    Am J Clin Oncol; 1996 Feb; 19(1):23-5. PubMed ID: 8554030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
    Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
    Meropol NJ; Petrelli NJ; Rustum YM; Rodriguez-Bigas M; Blumenson LE; Frank C; Berghorn E; Creaven PJ
    Invest New Drugs; 1995; 13(2):149-55. PubMed ID: 8617578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
    J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan.
    Wang WS; Fan FS; Hsieh RK; Chiou TJ; Lin JK; Lin TC; Yen CC; Liu JH; Hsu H; Chen PM
    Jpn J Clin Oncol; 1997 Jun; 27(3):174-9. PubMed ID: 9255273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent modulation of 5-fluorouracil with methotrexate and L-leucovorin: an effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma. A multicenter phase II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Lorusso V; Casaretti R; De Lucia L; Cartení G; Manzione L; Mancarella S; De Lena M; Comella G
    Tumori; 1999; 85(6):465-72. PubMed ID: 10774567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    de Gramont A; Louvet C; André T; Tournigand C; Krulik M
    Eur J Cancer; 1998 Apr; 34(5):619-26. PubMed ID: 9713264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.
    O'Connell MJ; Mailliard JA; Kahn MJ; Macdonald JS; Haller DG; Mayer RJ; Wieand HS
    J Clin Oncol; 1997 Jan; 15(1):246-50. PubMed ID: 8996149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
    Blanke CD; Kasimis B; Schein P; Capizzi R; Kurman M
    J Clin Oncol; 1997 Mar; 15(3):915-20. PubMed ID: 9060528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
    Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
    Baumgaertner I; Quinaux E; Khalil A; Louvet C; Buyse M; de Gramont A; André T;
    Clin Colorectal Cancer; 2010 Apr; 9(2):E5-10. PubMed ID: 20378497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
    Loeffler TM; Hausamen TU
    J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.
    Bar-Sela G; Haim N
    Med Oncol; 2004; 21(3):251-4. PubMed ID: 15456952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.